Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

which reported in March 2024 that—in a trial of more than 3,500 people with type 2 diabetes—Ozempic lowered the risk of kidney disease progression and death from kidney or cardiovascular ...

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama ... was made following a clinical trial of more than 3,500 people where ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Opens in a new tab or window The FDA approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening ... supported by the phase IIIb FLOW trial of 3,533 adults with type 2 diabetes ...

about a third of adults with diabetes also have chronic kidney disease, according to the U.S. Centers for Disease Control and Prevention. The clinical trial tested the efficacy of Ozempic when ...